drugset
drugset / Trial / NCT01085578

CG400549 Single Ascending Dose Study

NCT01085578 ↗

Phase 1 Completed 18 enrolled CrystalGenomics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

Evaluation of Safety, Tolerability and Pharmacokinetic Characteristics of CG400549 in Healthy Volunteers

Timeline

Start
2009-10
Primary completion
2009-12
Completion
2009-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator CG400549 Small molecule 80 mg Oral
Comparator CG400549 Small molecule 160 mg Oral
Comparator CG400549 Small molecule 320 mg Oral
Comparator CG400549 Small molecule 640 mg Oral
Comparator CG400549 Small molecule 1280 mg Oral
Comparator CG400549 Small molecule 1920 mg Oral

Indications

No indication recorded.